SomaLogic, Inc. (SLGC)

2.3300 -0.0100 (-0.43%) As of 09:40AM EDT. Market open.

SomaLogic, Inc.

2945 Wilderness Place
Boulder, CO 80301
United States
303 625 9000
https://www.somalogic.com

Sector(s): Healthcare
Industry: Health Information Services
Full-time employees: 451

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Stephen A. Williams BS, MB, Ph.D.	Chief Medical Officer	648.03k	N/A	1960
Mr. Adam Taich	Interim CEO	N/A	N/A	1975
Mr. Eliot M. Lurier CPA, CPA	Interim Chief Financial Officer	N/A	N/A	1958
Mr. Pi Zheng	Interim Chief Accounting Officer	N/A	N/A	1973
Dr. Jason Cleveland Ph.D.	Chief Technology Officer	N/A	N/A	N/A
Dr. Nebojsa Janjic Ph.D.	Chief Science Officer	N/A	N/A	1961
Mr. Ruben Gutierrez J.D.	Gen. Counsel	N/A	N/A	1975
Ms. Alison Marie Roelke	Chief People Officer	N/A	N/A	1975
Dr. Shane Bowen Ph.D.	Chief R&D Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.

Corporate governance

SomaLogic, Inc.’s ISS governance QualityScore as of 1 September 2023 is 10. The pillar scores are Audit: 10; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.